Peringatan Keamanan

bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding

Epirubicin

DB00445

small molecule approved

Deskripsi

An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

Struktur Molekul 2D

Berat 543.5193
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively
Volume Distribusi * 21 ± 2 L/kg [60 mg/m2 Dose] * 27 ± 11 L/kg [75 mg/m2 Dose] * 23 ± 7 L/kg [120 mg/m2 Dose] * 21 ± 7 L/kg [150 mg/m2 Dose]
Klirens (Clearance) * 65 +/- 8 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 60 mg/m2] * 83 +/- 14 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 75 mg/m2] * 65 +/- 13 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 120 mg/m2] * 69 +/- 13 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 150 mg/m2]

Absorpsi

100%

Metabolisme

Extensively and rapidly metabolized in the liver. Epirubicin is also metabolized by other organs and cells, including red blood cells. The four main metabolic routes are: (1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol exhibits in vitro cytoxic activity (~10% that of epirubicin), but it is unlikely to reach sufficient concentrations in vivo to produce cytotoxic effects.

Rute Eliminasi

Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion.

Interaksi Makanan

1 Data
  • 1. Drink plenty of fluids. Increased fluid intake increases urine output and the excretion of uric acid.

Interaksi Obat

559 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Epirubicin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Epirubicin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Epirubicin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Epirubicin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Epirubicin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Epirubicin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Epirubicin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Epirubicin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Epirubicin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Epirubicin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Epirubicin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epirubicin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Epirubicin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Epirubicin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Epirubicin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Epirubicin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Epirubicin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Epirubicin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Epirubicin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epirubicin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Epirubicin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epirubicin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Epirubicin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Epirubicin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epirubicin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Epirubicin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Epirubicin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Epirubicin.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Epirubicin.
Cladribine Epirubicin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Epirubicin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Epirubicin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Epirubicin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Epirubicin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Epirubicin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Epirubicin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Epirubicin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Epirubicin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Epirubicin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Epirubicin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Epirubicin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Epirubicin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Epirubicin.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Epirubicin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Epirubicin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Epirubicin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Epirubicin.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Epirubicin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Epirubicin is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Epirubicin is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Epirubicin is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Epirubicin is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Epirubicin is combined with Cisplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Epirubicin is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Epirubicin is combined with Vincristine.
Propylthiouracil The risk or severity of adverse effects can be increased when Epirubicin is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Epirubicin is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Epirubicin is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Epirubicin is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Epirubicin is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Epirubicin is combined with Linezolid.
Triamcinolone The risk or severity of adverse effects can be increased when Epirubicin is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Epirubicin is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Epirubicin is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Epirubicin is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Epirubicin is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Epirubicin is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Daunorubicin.
Tretinoin The risk or severity of cardiotoxicity can be increased when Epirubicin is combined with Tretinoin.
Irinotecan The risk or severity of adverse effects can be increased when Epirubicin is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Epirubicin is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Epirubicin is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Epirubicin is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Epirubicin is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Epirubicin is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Epirubicin is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Epirubicin is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Epirubicin is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Epirubicin is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Epirubicin is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Epirubicin is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Epirubicin is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Epirubicin is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Epirubicin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Epirubicin is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Epirubicin is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Epirubicin is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Epirubicin is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Epirubicin is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Epirubicin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Epirubicin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Epirubicin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Epirubicin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Epirubicin is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Epirubicin is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Epirubicin is combined with Trilostane.

Target Protein

DNA topoisomerase 2-beta TOP2B
DNA
DNA topoisomerase 2-alpha TOP2A

Referensi & Sumber

Synthesis reference: Marcel van der Rijst, Johan Wilhelm Scheeren, Dick de Vos, "Process for preparing epirubicin or acid addition salts thereof from daunorubicin." U.S. Patent US5874550, issued September, 1996.

Contoh Produk & Brand

Produk: 42 • International brands: 2
Produk
  • Ellence
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Ellence
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Epirubicin for Injection
    Solution • 2 mg / mL • Intravenous • Canada • Approved
  • Epirubicin Hydrochloride
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Epirubicin Hydrochloride
    Injection, solution • 2 mg/1mL • Intravenous • US • Approved
  • Epirubicin Hydrochloride
    Injection, solution • 2 mg/1mL • Intravenous • US • Generic • Approved
  • Epirubicin Hydrochloride
    Injection, powder, lyophilized, for solution • 50 mg/25mL • Intravenous • US • Approved
  • Epirubicin Hydrochloride
    Injection, powder, lyophilized, for solution • 200 mg/100mL • Intravenous • US • Approved
Menampilkan 8 dari 42 produk.
International Brands
  • Epirubicin Ebewe
  • Pharmorubicin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul